Half-life, duration of benefit and detection window are different questions. The reviewed sources do not establish dependable human values for MOTS-c. A blood degradation experiment and analytical assay cannot substitute for repeated sampling after a defined human administration.
FDA found no pharmacokinetic study in people or animals
FDA reviewed MOTS-c for its July 2026 advisory meeting and looked for exactly this kind of data. Its briefing reports the gap plainly:
At the time of this evaluation, the nominator did not submit, and FDA did not identify in-vivo pharmacokinetic or toxicokinetic studies of MOTS-c.[1]
FDA’s briefing did not identify in-vivo PKor toxicokinetic studies. That is the scope of the regulator’s reviewed evidence, not proof every experiment is known. Neither the blood experiment nor the current trial’s posted protocol establishes a dependable human half-life or clearance schedule.
In a lab dish, MOTS-c broke down fast in human blood
A relevant laboratory experiment is a 2019 study by an anti-doping lab in Cologne [2]. Researchers added MOTS-c to human whole blood and incubated it for 15 or 60 minutes. Enzymes in the blood quickly trimmed the 16-amino-acid peptide into four shorter fragments.
FDA's reading of that result is cautious. It says it "remains to be determined" whether MOTS-c given to a person can reach active levels in the body over time [1]. A test tube isn't a body, so the study shows fast breakdown in blood. It doesn't give a half-life.
Swallowed MOTS-c faces digestion on top of that. In a 2023 mouse study of colitis, MOTS-c given by mouth produced no significant benefit, while injected MOTS-c and a chemically modified oral version did [4]. The reviewed sources do not establish human oral bioavailability.
Your body already makes MOTS-c, which complicates the question
MOTS-c is made naturally from a gene in your mitochondria, so it's in your blood whether or not you take it. That makes "how long does it stay" a harder question than for an ordinary drug. Any measurement has to tell added MOTS-c apart from what you produce.
Ozkaya’s 85-person study reported serum means near 14 pg/mL [3]. Knoop’s 20-person ELISA measurements were 45.9–218.5 ng/mL and were not confirmed by LC/MS [2]. A nanogram equals 1,000 picograms: the quoted values differ by several thousand-fold, not merely 1,000-fold. Different populations and assays also mean this is not a paired head-to-head accuracy comparison.
| Question | Answer | Source |
|---|---|---|
| Half-life in people | Not established by reviewed sources | FDA briefing, July 2026 [1] |
| Half-life in animals | No in-vivo study identified | FDA briefing, July 2026 |
| Breakdown in human blood (lab dish) | Rapid, into 4 shorter fragments | Knoop 2019 [2] |
| Natural blood levels | Values differ by several thousand-fold across separate studies and methods | Knoop 2019; Ozkaya 2025 [3] |
| Can a sports test detect it? | Yes: a validated plasma test, detection limit 100 pg/mL | Knoop 2019 |
| How long after use it can be detected | Not published | Not established by reviewed sources |
| WADA status | Named under S4.4.1, prohibited at all times | WADA 2026 list [5] |
Anti-doping labs can test for MOTS-c
The Cologne group built its test for doping control. It uses liquid chromatography and mass spectrometry (LC/MS) on plasma and was validated under WADA's International Standard for Laboratories [2]. Its lower limit of detection is 100 pg/mL.
The test also looks for the four fragments seen in the blood experiment and two oxidized forms of MOTS-c. The authors say that could make use easier to trace, because fragments may linger after the intact peptide is gone. This analytical report does not establish a human detection window after administration. Assay sensitivity and laboratory breakdown are different measurements from how long a test remains positive in a person.
WADA names MOTS-c and bans it at all times
WADA's 2026 Prohibited List puts MOTS-c in section S4.4.1, under metabolic modulators. The entry reads: "Activators of the AMP-activated protein kinase (AMPK), e.g. ... AICAR, mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)" [5].
Section S4 is labeled prohibited at all times, in and out of competition. So an athlete in a tested sport can't use MOTS-c in the off-season and count on it clearing. FDA's briefing also notes that the Global Drug Reference Online database lists MOTS-c as prohibited [1].
Where the other MOTS-c questions are answered
How long effects might take to show is a different question, covered in how long MOTS-c takes to work. The fat-loss evidence, all from mice, is in does MOTS-c burn fat. FDA's position is on is MOTS-c FDA-approved. How this site judges providers that sell peptides is on how we check.